Mazyar Shadman, MD, MPH

The SEQUOIA arm D study demonstrates promising outcomes for treatment-naive patients with CLL, including high-risk patients.

Focusing on the future of CLL/SLL treatment, Mazyar Shadman, MD, MPH, discusses promising therapies in the pipeline.

Following EHA 2024, an expert on hematologic malignancies provides key takeaways and reviews additional data updates on treatments for CLL/SLL.

Mazyar Shadman, MD, MPH, shares comprehensive insights on the latest analyses of zanubrutinib compared with other BTK inhibitors in relapsed/refractory CLL/SLL.

An expert on CLL/SLL provides clinical insights on approaching the treatment of patients who progress beyond initial therapy.

Mazyar Shadman, MD, MPH, discusses the safety profile of BTK inhibitors in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Following recent updates from the SEQUOIA Arm D and CAPTIVATE studies, Mazyar Shadman, MD, MPH, discusses the future implications of fixed-duration therapy for patients with CLL/SLL.

An expert on hematologic malignancies discusses the ongoing CAPTIVATE trial evaluating ibrutinib plus venetoclax in patients with treatment-naïve CLL/SLL.

Mazyar Shadman, MD, MPH, describes his clinical approach to treating patients with high-risk CLL/SLL, including those with or without del(17p) or TP53 mutations.

Mazyar Shadman, MD, MPH, explains how community oncologists can care for their patient after they have been treated with chimeric antigen receptor T cells.

Mazyar Shadman, MD, MPH, discusses the results of his research on MB-106 as treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the phase 1/2 clinical trial of MB-106 for patients with CD20 positive B-cell malignancies.

Mazyar Shadman, MD, MPH, discusses the use of MB-106 for the treatment of patients with relapsed or refractory B-cell nonHodgkin lymphoma and chronic lymphocytic leukemia.